Zhongshan Ophthalmic Center, Sun Yat-sen University
Phase
Observational
Started
2022-11-01
Last updated
2023-01-31
Condition(s) studied
Amblyopia
Investigational drug(s) / intervention(s)
standard amblyopia treatment
standard amblyopia treatment: amblyopia treatment following international guidelines and genetic tests.
Study summary
This prospective study aims to observe the predictive effect of peripheral blood plasma biomarker on the outcome of treatment in children with different types of amblyopia. We also investigated the mechanism of neuromodulation in the visual development of amblyopic children.
Eligibility
Sex
ALL
Min age
3 Years
Max age
12 Years
Healthy volunteers
Accepted
Inclusion Criteria:
* Diagnosed with amblyopia
* 3-12 years of age
* Able to tolerate amblyopia treatment
* Agree to be involved in this study and agree to have a follow up visit every 3 months.
Exclusion Criteria:
* Have previous treatment history before
* Have pathological ocular anomalies known to cause reduced visual acuity
* Have previous psychiatric, visual or neurological disorders
* Have eccentric fixation and/or abnormal retinal correspondence
* Have attention disorder and learning disability that cannot comprehend psychophysical test instructions given and/or consent for themselves
Primary outcome measure(s)
Plasma protein predictor screening for visual acuity improvement following amblyopia therapy using Tandem Mass Tags proteomics — 2 years after including into this clinical trial Peripheral blood will be collected prior and after treatment. The plasma will be separated and Tandem Mass Tags will be used for proteomics. We will detect the different expression of plasma protein between successfully treated and untreated amblyopia patients to find biomarkers that predict amblyopia treatment success. Amblyopia treatment success is defined as best corrected visual acuity (BCVA) improvement of 3 or more logMAR lines.
Trial sites (1)
Facility
City
Region
Status
Zhongshan Ophthalmic Center
Guangzhou
Guangdong
Recruiting
More Zhongshan Ophthalmic Center, Sun Yat-sen University trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.